The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.
作者信息
Wilkie Martin
机构信息
Sheffield Kidney Institute, Sorby Renal Unit, Northern General Hospital, Sheffield, UK.
出版信息
Perit Dial Int. 2012 Sep-Oct;32(5):489-92. doi: 10.3747/pdi.2012.00204.
Abstract
摘要
相似文献
1
The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.平衡研究——强化关于低葡萄糖降解产物的中性pH值溶液的证据
Perit Dial Int. 2012 Sep-Oct;32(5):489-92. doi: 10.3747/pdi.2012.00204.
2
The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.生物相容型与标准腹膜透析液对腹膜炎微生物学、治疗和结局影响的比较：balANZ 试验。
Perit Dial Int. 2012 Sep-Oct;32(5):497-506. doi: 10.3747/pdi.2012.00052.
3
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.生物相容性与标准液对腹膜透析结果的影响。
J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.
4
Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.中性 pH、低葡萄糖降解产物腹膜透析液与标准液的经济学评价：BALANZ 试验的二次分析。
Am J Kidney Dis. 2015 May;65(5):773-9. doi: 10.1053/j.ajkd.2014.12.017. Epub 2015 Mar 4.
5
Biocompatible dialysis fluids for peritoneal dialysis.用于腹膜透析的生物相容性透析液。
Cochrane Database Syst Rev. 2014 Mar 27(3):CD007554. doi: 10.1002/14651858.CD007554.pub2.
6
Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.中性pH、低葡萄糖降解产物腹膜透析液对残余肾功能、尿量及超滤的影响：一项系统评价和Meta分析
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1380-8. doi: 10.2215/CJN.05410514. Epub 2015 Jun 5.
7
"Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?“生物相容性”中性pH低葡萄糖降解产物腹膜透析液：小题大做？
Semin Dial. 2017 Mar;30(2):164-173. doi: 10.1111/sdi.12579.
8
The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.中性 pH 腹膜透析液中葡萄糖降解产物减少对腹膜透析患者临床结局的影响。
Kidney Int. 2013 Nov;84(5):969-79. doi: 10.1038/ki.2013.190. Epub 2013 May 22.
9
Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?使用中性 pH 值、低葡萄糖降解产物的腹膜透析液是否会带来更好的患者预后？
Curr Opin Nephrol Hypertens. 2014 Mar;23(2):192-7. doi: 10.1097/01.mnh.0000441046.13912.1f.
10
Balance about balANZ.关于平衡（balANZ）的平衡。 （注：这里的“balANZ”看起来像是个特定名称或术语，直接保留英文，整体翻译可能不太符合常规语境，推测原文可能有误，正常应该是“Balance about balance”之类更通顺的表述，但按照要求逐字翻译是这样。）
Perit Dial Int. 2012 Sep-Oct;32(5):493-6. doi: 10.3747/pdi.2012.00225.
本文引用的文献
1
The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.低糖降解产物、中性 pH 值与标准腹膜透析液对腹膜功能影响的研究：balANZ 试验。
Nephrol Dial Transplant. 2012 Dec;27(12):4445-53. doi: 10.1093/ndt/gfs314. Epub 2012 Aug 1.
2
Trials (and tribulations) of biocompatible peritoneal dialysis fluids.生物相容性腹膜透析液的试验（及磨难）
Perit Dial Int. 2012 May-Jun;32(3):247-51. doi: 10.3747/pdi.2012.00044.
3
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.生物相容性与标准液对腹膜透析结果的影响。
J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.
4
Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.腹透液中伊可定、葡萄糖碳酸氢盐/乳酸盐对新发患者腹腔内白细胞介素 6 信号转导的影响。
Perit Dial Int. 2012 Jan-Feb;32(1):37-44. doi: 10.3747/pdi.2010.00235.
5
Novel peritoneal dialysis solutions--what are the clinical implications?新型腹膜透析液——临床意义如何？
Blood Purif. 2012;33(1-3):153-9. doi: 10.1159/000334151. Epub 2012 Jan 20.
6
UK Renal Registry 13th Annual Report (December 2010): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses.英国肾脏登记册第 13 份年度报告（2010 年 12 月）：第二章：2009 年英国 RRT 的患病率：全国和各中心的具体分析。
Nephron Clin Pract. 2011;119 Suppl 2:c27-52. doi: 10.1159/000331744. Epub 2011 Aug 26.
7
ISPD position statement on reducing the risks of peritoneal dialysis-related infections.国际腹膜透析学会关于降低腹膜透析相关感染风险的立场声明。
Perit Dial Int. 2011 Nov-Dec;31(6):614-30. doi: 10.3747/pdi.2011.00057. Epub 2011 Aug 31.
8
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.将患者随机分配到生物相容或常规腹膜透析溶液的长期随访结果显示，腹膜炎或技术生存率无差异。
Kidney Int. 2011 Nov;80(9):986-991. doi: 10.1038/ki.2011.244. Epub 2011 Aug 3.
9
Peritoneal dialysis-associated peritonitis rates and outcomes in a national cohort are not improving in the post-millennium (2000-2007).在千年之交后（2000-2007 年），全国队列中腹膜透析相关性腹膜炎的发生率和结局并未改善。
Perit Dial Int. 2011 Nov-Dec;31(6):639-50. doi: 10.3747/pdi.2010.00185. Epub 2011 Jul 31.
10
Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.澳大利亚腹膜透析患者腹膜炎的微生物学和结局。
Perit Dial Int. 2011 Nov-Dec;31(6):651-62. doi: 10.3747/pdi.2010.00131. Epub 2011 Jun 30.
Zotero 插件